NorthSea Raises Cash For NASH Program

 
• By Lucie Ellis-Taitt

NorthSea raises €25m to push icosabutate, its only clinical compound, which was licensed from Pronova BioPharma, into Phase IIb trials for fatty liver disease. The drug has previously been tested in hypertriglyceridemia and dyslipidemia.

Liver anatomy
NTS to pursue icosabutate in NASH

More from Strategy

More from Business